Trading Update

RNS Number:4720U
Maelor PLC
05 April 2007

5 April 2007

                     Maelor plc ("Maelor" or the "Company")

                     Pre-Close Statement and Trading update

The Board of Maelor plc (AIM:MLR), the specialist critical care company is
pleased to announce that it expects the outcome for the full year to 31st March
2007 to be ahead of current market expectations.

The positive trading highlighted at the Company's Interim Results on 2nd
November 2006 has been sustained into the last quarter of the financial year and
the Board anticipates a significant reduction in losses for the second half of
the financial year. The sales growth of Volplex, a plasma substitute product,
the commercialisation of which has been taken in-house, has continued, driven by
active promotion and successful tendering for regional contracts.  Sales of
catheter flushing devices also continue to progress well.

The Company is actively building its specialist critical care portfolio having
recently further added to its "specials" portfolio a fluid and volume
replacement product as well as AquiHex, a product that the Company has
developed, for use in hospital infection control.  In parallel, late stage
development of its complementary plasma substitute product, ISOplex, is
progressing to schedule with approval still targeted for late 2008.

Commenting on the Company's performance Tim Wright CEO said:

"We are very pleased with the progress that Maelor has made since the strategic
review in June 2006.  In line with our new strategy the business is now focused,
stabilised and well positioned for rapid organic and acquisitive growth.  The
acquisition of Acorus announced separately today represents a further step in
our strategy to establish a significant business in hospital specialist 
medicine"

                                    - Ends -

For further information, call:

Tim Wright, Maelor plc -  01244 625150

Billy Clegg/Edward Westropp, Financial Dynamics - 020 7831 3113

Matthew Hall, Noble & Company - 020 7763 2200


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

TSTIFFLLSDISIID